Compare AstraZeneca plc (AZN) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Redwire Corporation — how do they compare? AstraZeneca plc trades at $167.12 (market cap $253.13B), while Redwire Corporation trades at $10.07 (market cap $2.33B). The key difference: AstraZeneca plc is far larger — about 108.6× Redwire Corporation's market cap, and AstraZeneca plc pays a 1.92% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals.
| AZN | RDW | |
|---|---|---|
Market Cap | $253.13B | $2.33B |
Sector | Health | Technology |
52-Week High | $209.48 | $25.90 |
52-Week Low | $137.44 | $5.06 |
Enterprise Value | $279.37B | $2.39B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
RDW trades at $9.59, down 5.8% with bearish technical signals despite 80% analyst buy ratings. The company shows significant revenue growth but deep losses, with net income margin at -80.9% and negative cash flow from operations. Recent news highlights dilution concerns from a $500M stock offering and competitive pressure from SpaceX's market dominance.
The stock presents high-risk potential with analyst consensus target of $19.00 representing 98% upside, but requires improved profitability and reduced cash burn. Key risks include persistent losses, dilution from financing activities, and intense space sector competition that could limit near-term recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
